Mackenzie Financial
CTMX icon

Mackenzie Financial’s CytomX Therapeutics CTMX Stock Holding History

Mackenzie Financial’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,138
Closed -$39.5K – 1558
2024
Q1 		$39.5K Sell
18,138
-1,541
-8% -$2.84K ﹤0.01% 1493
2023
Q4 		$30.5K Buy
19,679
+4,042
+26% +$5.32K ﹤0.01% 1473
2023
Q3 		$19.4K Buy
+15,637
New +$24.6K ﹤0.01% 1453
2023
Q1 		– Sell
-15,639
Closed -$25K – 1537
2022
Q4 		$25K Hold
15,639
– – ﹤0.01% 1392
2022
Q3 		$23K Hold
15,639
– – ﹤0.01% 1403
2022
Q2 		$29K Buy
15,639
+2,399
+18% +$4.59K ﹤0.01% 1419
2022
Q1 		$35K Buy
+13,240
New +$50.8K ﹤0.01% 1380

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Mackenzie Financial's CTMX Position: Q2 2024 in Review

Mackenzie Financial sold out of CytomX Therapeutics (CTMX) in Q2 2024, closing a stake of 18,138 shares — an estimated $39.5K sold.

Mackenzie Financial first reported a position in CTMX in Q1 2022 and held it in 7 quarters. The position peaked at $39.5K in Q1 2024. 74 funds tracked by Wall St. Rank hold CTMX as of Q2 2024.

  • Mackenzie Financial reported no remaining CytomX Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Mackenzie Financial sold 18,138 CytomX Therapeutics shares in Q2 2024, an estimated $39.5K.
  • Mackenzie Financial first reported a position in CytomX Therapeutics in Q1 2022 and held it in 7 quarters.
  • Mackenzie Financial's CytomX Therapeutics position peaked at $39.5K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2024.

Based on Mackenzie Financial's 13F filing for Q2 2024, filed 14 Aug 2024.